139 related articles for article (PubMed ID: 38489494)
1. Viremia and HIV Drug Resistance Among People Receiving Dolutegravir Versus Efavirenz-Based First-Line Antiretroviral Therapy.
Dorward J; Sookrajh Y; Lessells R; Bulo E; Bodley N; Singh L; Moodley P; Samsunder N; Drain PK; Hayward G; Butler CC; Garrett N
J Acquir Immune Defic Syndr; 2024 Apr; 95(5):e8-e11. PubMed ID: 38489494
[TBL] [Abstract][Full Text] [Related]
2. Urine tenofovir and dried blood spot tenofovir diphosphate concentrations and viraemia in people taking efavirenz and dolutegravir-based antiretroviral therapy.
Dorward J; Govender K; Moodley P; Lessells R; Samsunder N; Sookrajh Y; Fanshawe TR; Turner PJ; Butler CC; Drain PK; Hayward GN; Garrett N
AIDS; 2024 Apr; 38(5):697-702. PubMed ID: 38126342
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
[TBL] [Abstract][Full Text] [Related]
5. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
[TBL] [Abstract][Full Text] [Related]
6. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
7. Neurotoxicities in the treatment of HIV between dolutegravir, rilpivirine and dolutegravir/rilpivirine: a meta-analysis.
Allen Reeves A; Fuentes AV; Caballero J; Thomas JE; Mosley Ii JF; Harrington C
Sex Transm Infect; 2021 Jun; 97(4):261-267. PubMed ID: 33782144
[TBL] [Abstract][Full Text] [Related]
8. Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.
Haas DW; Acosta EP
Clin Infect Dis; 2021 May; 72(10):1820-1822. PubMed ID: 32667979
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
[TBL] [Abstract][Full Text] [Related]
10. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
[TBL] [Abstract][Full Text] [Related]
11. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
[TBL] [Abstract][Full Text] [Related]
12. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Huang SH; Huang YC; Su YC; Liu WC; Hung CC
Int J Infect Dis; 2021 Apr; 105():147-151. PubMed ID: 33592339
[TBL] [Abstract][Full Text] [Related]
13. Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings.
Maartens G; Boffito M; Flexner CW
Curr Opin HIV AIDS; 2017 Jul; 12(4):355-358. PubMed ID: 28403028
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dolutegravir and efavirenz on depression, anxiety and sleep disorders in pregnant and postpartum women living with HIV.
van der Wekken-Pas L; Nassiwa S; Malaba T; Lamorde M; Myer L; Waitt C; Reynolds H; Khoo S; He N; van Leeuwen L; Burger D; Wang D; Colbers A
AIDS; 2024 Jun; 38(7):975-981. PubMed ID: 38277390
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of Single-Dose Versus Double-Dose Dolutegravir After Switching From a Failing Efavirenz-Based Regimen.
Griesel R; Banda CG; Zhao Y; Omar Z; Wiesner L; Meintjes G; Sinxadi P; Maartens G
J Acquir Immune Defic Syndr; 2024 May; 96(1):85-91. PubMed ID: 38372621
[TBL] [Abstract][Full Text] [Related]
16. Dolutegravir for second-line antiretroviral therapy: the beat goes on.
Shangase N; Kufa T
Lancet Glob Health; 2024 Feb; 12(2):e183-e184. PubMed ID: 38142693
[No Abstract] [Full Text] [Related]
17. Point-of-Care Detection of Nonadherence to Antiretroviral Treatment for HIV-1 in Resource-Limited Settings Using Drug Level Testing for Efavirenz, Lopinavir, and Dolutegravir: A Validation and Pharmacokinetic Simulation Study.
Hermans LE; Nijhuis M; Tempelman HA; Houts T; Schuurman R; Burger DM; Wensing AMJ; ter Heine R
J Acquir Immune Defic Syndr; 2021 Aug; 87(4):1072-1078. PubMed ID: 34153013
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
19. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
[TBL] [Abstract][Full Text] [Related]
20. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
